晚期胆道癌免疫检查点抑制剂治疗的研究进展

马佳曼 杨雨

马佳曼, 杨雨. 晚期胆道癌免疫检查点抑制剂治疗的研究进展[J]. 中国肿瘤临床, 2023, 50(22): 1168-1173. doi: 10.12354/j.issn.1000-8179.2023.20230982
引用本文: 马佳曼, 杨雨. 晚期胆道癌免疫检查点抑制剂治疗的研究进展[J]. 中国肿瘤临床, 2023, 50(22): 1168-1173. doi: 10.12354/j.issn.1000-8179.2023.20230982
Jiaman Ma, Yu Yang. Progress research on immune checkpoint inhibitors for advanced biliary tract cancer treatment[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(22): 1168-1173. doi: 10.12354/j.issn.1000-8179.2023.20230982
Citation: Jiaman Ma, Yu Yang. Progress research on immune checkpoint inhibitors for advanced biliary tract cancer treatment[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(22): 1168-1173. doi: 10.12354/j.issn.1000-8179.2023.20230982

晚期胆道癌免疫检查点抑制剂治疗的研究进展

doi: 10.12354/j.issn.1000-8179.2023.20230982
详细信息
    作者简介:

    马佳曼:专业方向为腹部肿瘤内科临床诊治与研究

    通讯作者:

    杨雨 yangyu@wchscu.cn

Progress research on immune checkpoint inhibitors for advanced biliary tract cancer treatment

More Information
  • 摘要: 胆道恶性肿瘤(biliary tract cancers,BTC)主要包括胆囊癌和肝内外胆管癌,绝大多数为腺癌,侵袭性较强且预后较差。BTC发病隐匿,即便可手术切除患者仍面临较高复发风险,术后辅助化疗生存获益有限。系统抗肿瘤药物治疗是不可手术切除或转移性BTC的主要治疗手段。近年来,除传统化疗外,免疫检查点抑制剂和分子靶向药物在晚期BTC治疗中也取得较大进展,极大丰富了临床治疗选择,也进一步改善了患者预后。一线化疗联合免疫治疗较传统化疗已成为优势治疗策略,化疗联合免疫治疗和抗血管生成靶向治疗以及化疗联合双免疫治疗显示出较好的前景,二线免疫联合治疗也进行了积极探索。本文就晚期胆道癌的免疫治疗现状与最新进展进行综述。

     

  • 表  1  晚期胆道癌免疫治疗部分研究进展

    研究研究方案例数ORR(%)mPFS(月)mOS(月)
    一线治疗
    化疗+免疫TOPAZ-1(Ⅲ期)
    GC化疗+度伐利尤单抗vs.
    GC化疗+安慰剂
    341vs. 34426.7 vs. 18.77.2 vs. 5.712.8 vs. 11.5
    KEYNOTE-966
    (Ⅲ期)
    GC化疗+帕博利珠单抗vs.
    GC化疗+安慰剂
    533 vs. 53629.0 vs. 29.06.5 vs. 5.612.7 vs. 10.9
    Ⅱ期GC化疗+信迪利单抗3036.75.115.9
    Ⅱ期GS化疗+特瑞普利单抗5030.67.015.0
    化疗+免疫+
    抗血管靶向
    Ⅱ期(ICC)
    GEMOX化疗+特瑞普利单抗+仑伐替尼3080.010.0未达到
    SAGC研究
    (Ⅱ期)
    GC化疗+信迪利单抗+安罗替尼vs. GC化疗40 vs. 4052.8 vs. 29.48.6 vs. 6.2未达到
    IMbrave151 (Ⅱ期)GC化疗+阿替利珠单抗+贝伐珠单抗vs.
    GC化疗+阿替利珠单抗+安慰剂
    79 vs. 8324.1 vs. 25.38.3 vs. 7.9未达到vs. 11.4
    化疗+双免IMMUCHEC研究(Ⅱ期)D组(GC化疗+度伐利尤单抗1.5 g 每3周1次+替西木单抗300 mg×1次)30
    26.78.13
    22.73
    ≥二线治疗
    免疫单药KEYNOTE-158
    (Ⅱ期)
    帕博利珠单抗
    104
    (MSI-H 22例)
    5.8(40.9)2.0(4.2) 7.4(24.3)
    Ⅱ期纳武利尤单抗4622.03.6814.24
    前瞻性研究(PD-L1 阳性)帕博利珠单抗4012.51.5 4.3
    免疫联合LEAP-005(Ⅱ期)帕博利珠单抗+仑伐替尼3110.06.1 8.6
    I/Ⅱ期纳武利尤单抗+仑伐替尼26 9.42.5 6.4
    Ⅱ期帕博利珠单抗+仑伐替尼3225.04.911.0
    Ⅱ期信迪利单抗+安罗替尼2030.06.512.3
    Ⅱ期信迪利单抗+白蛋白紫杉醇2427.35.6312.6
    下载: 导出CSV
  • [1] Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9):557-588. doi: 10.1038/s41575-020-0310-z
    [2] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1):19-31.
    [3] Benavides M, Antón A, Gallego J, et al. Biliary tract cancers: SEOM clinical guidelines[J]. Clin Transl Oncol, 2015, 17(12):982-987. doi: 10.1007/s12094-015-1436-2
    [4] Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6:99-109.
    [5] Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer[J]. Lancet, 2021, 397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7
    [6] Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X
    [7] Razumilava N, Gores GJ. Cholangiocarcinoma[J]. Lancet, 2014, 383(9935):2168-2179. doi: 10.1016/S0140-6736(13)61903-0
    [8] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281. doi: 10.1056/NEJMoa0908721
    [9] Ioka T, Kanai M, Kobayashi S, et al. Randomized phase Ⅲ study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)[J]. J Hepatobiliary Pancreat Sci, 2023, 30(1):102-110. doi: 10.1002/jhbp.1219
    [10] Shroff Rachna T, Guthrie Katherine A, James SA, et al. SWOG 1815: a phase Ⅲ randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers[J]. J Clin Oncol, 2023, 41(4_suppl):LBA490. doi: 10.1200/JCO.2023.41.4_suppl.LBA490
    [11] Oh DY, Ruth He A, Qin SK, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer[J]. NEJM Evid, 2022, 1(8): EVIDoa2200015.
    [12] Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4
    [13] Zeng TM, Yang G, Lou C, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer[J]. Nat Commun, 2023, 14(1):1340. doi: 10.1038/s41467-023-37030-w
    [14] Li W, Wang Y, Yu Y, et al. Toripalimab combined with gemcitabine and S-1 in the first-line treatment of advanced biliary tract cancer[J]. Innovation (Camb), 2022, 3(4):100255.
    [15] Liu DL. Cancer biomarkers for targeted therapy[J]. Biomark Res, 2019, 7(1):1-7. doi: 10.1186/s40364-018-0153-8
    [16] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2
    [17] Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6
    [18] Qin SK, Chan SL, Gu SZ, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3
    [19] Zhou J, Fan J, Shi G, et al. 56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: a phase Ⅱ clinical trial[J]. Ann Oncol, 2020, 31:S262-S263.
    [20] Zhou J. A phase Ⅲ, randomized, three-arm, double-blind, placebo-controlled, international multi-center study to evaluate the efficacy and safety of toripalimab in combination with lenvatinib and gemcitabine-based chemotherapy compared with gemcitabine-based chemotherapy as first-line treatment in patients with unresectable advanced intrahepatic cholangiocarcinoma (ICC): NCT05342194[R/OL]. clinicaltrials. gov[2023-01-01]. https://clinicaltrials.gov/study/NCT05342194.
    [21] Liao JJ, Qi X, Wei Q, et al. A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC[J]. J Clin Oncol, 2022, 40(16): 4100.
    [22] El-Khoueiry A, Ren Z, Chon H, et al. IMbrave151: a phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer[J]. J Clin Oncol, 2023, 41(4_suppl):491. doi: 10.1200/JCO.2023.41.4_suppl.491
    [23] Abou-Alfa GK, Chan SL, Furuse J, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study[J]. J Clin Oncol, 2018, 36(15_suppl):TPS4144. doi: 10.1200/JCO.2018.36.15_suppl.TPS4144
    [24] Vogel A, Boeck S, Waidmann O, et al. 52MO A randomized phase Ⅱ trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)[J]. Ann Oncol, 2022, 33:S563.
    [25] Wang WT. Efficacy and safety of cadonilimab combined with gemcitabine and cisplatin in the first-line treatment of unresectable locally advanced or metastatic biliary malignancies: NCT05978609[R/OL]. clinicaltrials.gov[2023-01-01]. https://clinicaltrials.gov/study/NCT05978609.
    [26] Lamarca A, Palmer D, Wasan HS, et al. 54MO Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial[J]. Ann Oncol, 2022, 33:S564-S565. doi: 10.1016/j.annonc.2022.07.082
    [27] Kendall T, Verheij J, Gaudio E, et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma[J]. Liver Int, 2019, 39(suppl 1):7-18.
    [28] Lin JZ, Cao YH, Yang X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma[J]. Theranostics, 2021, 11(10):4585-4598. doi: 10.7150/thno.56539
    [29] Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020, 147(8):2190-2198. doi: 10.1002/ijc.33013
    [30] Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894. doi: 10.1001/jamaoncol.2020.0930
    [31] Luis V, Zarnie L, Cheol CHC, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study[J]. J Clin Oncol, 2021, 39(15_suppl):4080. doi: 10.1200/JCO.2021.39.15_suppl.4080
    [32] Ueno M, Morizane C, Ikeda M, et al. 64P Phase I/Ⅱ study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)[J]. Ann Oncol, 2022, 33:S569-S570.
    [33] Lin JZ, Yang X, Long JY, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma[J]. Hepatobiliary Surg Nutr, 2020, 9(4):414-424. doi: 10.21037/hbsn-20-338
    [34] Lin JZ, Shi W, Zhao SH, et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing[J]. J Clin Oncol, 2018, 36:500.
    [35] Jin SL, Zhao R, Zhou C, et al. Updated results from the phase Ⅱ study: efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers[J]. J Clin Oncol, 2023, 41(4):577-577.
    [36] Zhou J, Sun YK, Zhang W, et al. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis[J]. Hepatology, 2023, 77(1):65-76. doi: 10.1002/hep.32548
    [37] Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase Ⅱ trial[J]. Eur J Cancer, 2022, 162:161-169. doi: 10.1016/j.ejca.2021.11.012
    [38] Li XF, Zhou N, Yang Y, et al. Nab-paclitaxel plus anti–PD-1 antibody as second-line treatment for advanced biliary tract cancer: an investigator-initiated phase 2 study (NapaSinti trial)[J]. J Clin Oncol, 2023, 41(4):564
    [39] Kang J, Jeong JH, Hwang HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: tumor proportion score as a potential biomarker for response[J]. Cancer Res Treat, 2020, 52(2):594-603. doi: 10.4143/crt.2019.493
    [40] Valle JW, Qin S, Antonuzzo L, et al. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase Ⅲ study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)[J]. Ann Oncol, 2022, 33:S1457.
    [41] Li SM, Wu XW, Yan XQ, et al. Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma[J]. J Clin Oncol, 2022,( suppl.524): DOI: 10.1200/JCO.2022.40.6
    [42] Chung HC, Bang YJ, S Fuchs C, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: keynote-811[J]. Future Oncol, 2021, 17(5):491-501. doi: 10.2217/fon-2020-0737
    [43] Xiaoyong H. A randomized controlled, multicenter, open, seamless phase Ⅱ-Ⅲ clinical trial of PD1 antibody (toripalimab), lenvatinib and GEMOX neoadjuvant treatment for resectable intrahepatic chol angiocarcinoma with high-risk recurrence factors: NCT04669496[R/OL]. clinicaltrials.gov [2023-01-01]. https://clinicaltrials.gov/study/NCT04669496.
  • 加载中
表(1)
计量
  • 文章访问数:  99
  • HTML全文浏览量:  12
  • PDF下载量:  46
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-10-09
  • 录用日期:  2023-12-07
  • 修回日期:  2023-12-04

目录

    /

    返回文章
    返回